Day: January 16, 2026

VALENCIA, Spain, Jan. 16, 2026 (GLOBE NEWSWIRE) — Turbo Energy S.A. (Nasdaq: TURB) (“Turbo Energy” or the “Company”), a global provider of AI-optimized solar energy storage technologies and solutions, today announced that it received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on January 12, 2026, notifying the Company that it is no longer in compliance with Nasdaq Capital Market continued listing requirements. The Notice indicates that, based on the Company’s Form 6-K filed on November 4, 2025, reporting stockholders’ equity of approximately $1.5 million as of June 30, 2025, the Company does not currently meet the minimum stockholders’ equity requirement of $2.5 million for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(1)....

American Rebel Holdings Inc2026 is the year we turn distribution momentum into retail velocity at scale—and the way we do that is by stacking our network with high-execution, community-embedded distributors who win at the account level every single dayWith Virginia momentum already underway through Valley, Lawrence Distributing brings heavyweight local execution to amplify chain interest, shelf gains, and on-/off-premise growth for American Rebel Light NASHVILLE, TN, Jan. 16, 2026 (GLOBE NEWSWIRE) — In a release issued January 13, 2026 under the same headline by American Rebel Holdings, Inc. (NASDAQ: AREB), please note that a bullet point in the “Recent announced execution wins since September 2025 include:” section inadvertently contained third-party descriptive information that was not relevant to Lawrence Distributing...

MIAMI, Jan. 16, 2026 (GLOBE NEWSWIRE) — Inter (NASDAQ: INTR), the financial institution serving more than 41 million customers, has received regulatory approval from the Florida Office of Financial Regulation (OFR) and the Federal Reserve (FED) to establish a state‑licensed international banking branch in Florida, marking a significant milestone in its international expansion. The approval authorizes Inter to establish a Florida branch based in Miami, expanding the company’s cross-border capabilities and broadening its range of financial services for individuals and businesses. “This milestone strengthens our position as a global platform and enables us to deliver even more value to our clients across borders,” said João Vitor Menin, Global CEO of Inter. “The U.S. branch allows us to scale our offering, deliver...

NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) — Value Line, Inc. (NASDAQ: VALU) announced today that its Board of Directors declared on January 16, 2026 a quarterly cash dividend of $0.325 per common share, payable on February 10, 2026, to stockholders of record on January 26, 2026. The Company has 9,387,957 shares of common stock outstanding as of January 16, 2026. The Company also announced that the Board has appointed Dr. Alexander J. Swistel to its Board of Directors and as a member of the Board’s Audit Committee.         Value Line is a leading provider of investment research. The Value Line Investment Survey is one of the most widely used sources of independent equity research.         Value Line publishes proprietary investment research in separate print and digital formats.         Value Line provides these specialized services:...

NOTE TO READER – The news release of Endeavour Silver Corp. dated January 16, 2026, (the “News Release”) has been re-filed on SEDAR. The previously filed News Release had a typographical error on page 3 with respect to the AISC for Terronera. The consolidated AISC remains the same as the previously filed News Release. This news release replaces the previously filed News Release. VANCOUVER, British Columbia, Jan. 16, 2026 (GLOBE NEWSWIRE) — Endeavour Silver Corp. (“Endeavour” or the “Company”) (NYSE: EXK; TSX: EDR) announces its consolidated production and cost guidance for the Terronera, Guanaceví, and Kolpa mines, along with its capital and exploration budgets for 2026. All dollar amounts are in US dollars (US$) and ounces are troy ounces. 2026 Production and Cost Guidance Highlights In 2026, silver production from Terronera,...

BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) — Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the closing of its previously announced Company best efforts registered direct offering (“Offering”) of 7,040,000 ordinary shares at an offering price of $1.25 per ordinary share conducted without an underwriter or placement agent to members of senior management and existing shareholders. The gross proceeds to Tiziana from the Offering, before deducting estimated Offering expenses payable by Tiziana, were $8.8 million. For every ordinary share subscribed, participants will receive one warrant entitling the holder to subscribe for one new ordinary share at a price of $1.50 at any time up to and...

MELBOURNE, Australia, Jan. 17, 2026 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Biopsy of the Prostate Avoidance Stratification Study), a Phase 3 trial to evaluate the use of Telix’s commercial PSMA-PET1 imaging agents, Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) and Gozellix® (kit for the preparation of gallium Ga 68 gozetotide injection) in the initial prostate cancer diagnosis setting. The dose was administered under the supervision of Dr. Brian Mazzarella at Urology Austin and supplied by RLS Radiopharmacies. BiPASS™ is the first study designed to gain marketing authorization for 68Ga-PSMA-PET2 imaging in the pre-biopsy setting. The prospective, open-label...

Company AnnouncementBased on the topline results from the EPCORE® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss next stepsCOPENHAGEN, Denmark; January 16, 2026 – Genmab A/S (Nasdaq: GMAB) today announced topline results from the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, which demonstrated an improvement in progression-free survival (PFS) (HR: 0.74 [95% CI 0.60 to 0.92])* in patients treated with epcoritamab monotherapy. Additionally, improvements were observed in the complete response rate, duration of response, and time to next treatment among patients treated with epcoritamab monotherapy. EPCORE DLBCL-1 is the first Phase 3 study to demonstrate an improvement in PFS in patients with relapsed or refractory (R/R) diffuse large...